Trump administration ties pricing deals with another nine pharma companies
With the latest batch’s agreements, only three out of the 17 drugmakers initially targeted by Trump have not signed pricing deals.
With the latest batch’s agreements, only three out of the 17 drugmakers initially targeted by Trump have not signed pricing deals.
The partnership is the latest in a long line of AI-centric projects in drug discovery and development.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Huawei’s three key steps to drive industrial intelligence forward and unleash AI’s full potential
First responders see AI and other advanced tech as essential
What does the EU Data Act mean for businesses?
Trump blames Covid-19 drugmakers for fuelling CDC turmoil